CA
NZ
UK
AU
IND
US
Biotech spent much of the early 2020s as the market's problem child. In September 2026 the mood is noticeably different. A run of clinical readouts, a friendlier funding backdrop and renewed dealmaking appetite have pulledCapitalback toward the risk end of healthcare, and theNasdaqComposite, where …
Walk down the biotech aisle of theNasdaqComposite in September 2026 and you find no single mood. One company is booking hundreds of millions in new drug sales; another is nursing under $10 million in cash. One just watched a flagship depression program collapse; another …
Biotech used to trade as a single mood. In September 2026 it does not. The companies grouped under theNasdaqComposite's health-technology umbrella now range from pre-revenue science projects burning cash toward a first readout to profitable commercial machines raising full-year guidance. Sana Biotechnology (NASDAQ:SANA), Delcath …
Health technology rarely moves as one block. On any given week theNasdaqComposite carries a profitable imaging giant, a clinical-stage obesity play burning cash toward a distant readout, and a small-cap chasing its first product revenue, all filed under the same sector label. GE HealthCare …
Biotech remains one of the most idiosyncratic corners of theNasdaqComposite. These companies rarely move on macro data; they move on regulatory letters, trial readouts and cash runways. Achieve Life Sciences (NASDAQ:ACHV), Revolution Medicines (NASDAQ:RVMD), MBX Biosciences (NASDAQ:MBX), Prelude Therapeutics (NASDAQ:PRLD) and AN2 Therapeutics (NASDAQ:ANTX) …
Group APYX, AXSM, STOK, CRBP and COCH together and you get a fair cross-section of what healthcare means inside theNasdaqComposite this September. One is a small aesthetics-device maker fighting for operating leverage. One is a fast-scaling central-nervous-system drug company already selling three products. One …
TheNasdaqComposite is still shorthand for megacap technology, but tucked inside it is a cluster of healthcare-services companies whose fortunes turn on very different levers: clinician supply,Medicareand Medicaid rates, payer contracts and the slow grind toward operating profitability. Aveanna Healthcare (NASDAQ:AVAH), Starling Oncology (NASDAQ:STLN), NeoGenomics …
The U.S. cannabis sector in mid-September 2026 is defined by two parallel federal tracks: progress on marijuana rescheduling and a looming crackdown on most hemp-derived THC products. State markets keep growing, but operators still face oversupply, thin margins, and uneven access to capital.
BioVie Inc. (NASDAQ: BIVI) shares closed up 6% at $2.05 after the company entered into an at-the-market offering agreement with A.G.P. to issue and sell up to $6.46 million of Class A common stock for working capital and general corporate needs.
Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported that its Johnson & Johnson-partnered asset, JNJ-5120/PIPE-307, missed its primary endpoint within the Phase 2 MOONLIGHT-1 major depressive disorder study, failing to show a statistically significant MADRS total score reduction against placebo at Day 5.
Please wait processing your request...